메뉴 건너뛰기




Volumn 7, Issue 7, 2011, Pages 379-380

Rheumatoid arthritis: When should we use rituximab to treat RA?

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; METHOTREXATE; RITUXIMAB;

EID: 79959962714     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2011.79     Document Type: Short Survey
Times cited : (10)

References (9)
  • 1
    • 67650357875 scopus 로고    scopus 로고
    • Treatment of rheumatoid arthritis: We are getting there
    • Yazici, Y. Treatment of rheumatoid arthritis: we are getting there. Lancet 374, 178-180 (2009).
    • (2009) Lancet , vol.374 , pp. 178-180
    • Yazici, Y.1
  • 2
    • 79955806071 scopus 로고    scopus 로고
    • Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
    • Buch, M. H. et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 70, 909-920 (2011).
    • (2011) Ann. Rheum. Dis. , vol.70 , pp. 909-920
    • Buch, M.H.1
  • 3
    • 43949125192 scopus 로고    scopus 로고
    • Triple therapy in early active rheumatoid arthritis: A randomized single-blind controlled trial comparing step-up and parallel treatment strategies
    • Saunders, S. A. et al. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum. 58, 1310-1317 (2008).
    • (2008) Arthritis Rheum. , vol.58 , pp. 1310-1317
    • Saunders, S.A.1
  • 4
    • 73349096059 scopus 로고    scopus 로고
    • Evaluation of two strategies initial methotrexate monotherapy vs its combination with adalimumab in management of early active rheumatoid arthritis: Data from the guepard trial
    • Oxford
    • Soubrier, M. et al. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology (Oxford) 48, 1429-1434 (2009).
    • (2009) Rheumatology , vol.48 , pp. 1429-1434
    • Soubrier, M.1
  • 5
    • 77953703613 scopus 로고    scopus 로고
    • Treatment of rheumatoid arthritis: Strategies for achieving optimal outcomes
    • Gibofsky, A. & Yazici, Y. Treatment of rheumatoid arthritis: strategies for achieving optimal outcomes. Ann. Rheum. Dis. 69, 941-942 (2010).
    • (2010) Ann. Rheum. Dis. , vol.69 , pp. 941-942
    • Gibofsky, A.1    Yazici, Y.2
  • 6
    • 78650645377 scopus 로고    scopus 로고
    • Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: The image trial
    • Tak, P. P. et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann. Rheum. Dis. 70, 39-46 (2011).
    • (2011) Ann. Rheum. Dis. , vol.70 , pp. 39-46
    • Tak, P.P.1
  • 7
    • 48949117149 scopus 로고    scopus 로고
    • Tumor necrosis factor alpha inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritis
    • Yazici, Y. & Yazici, H. Tumor necrosis factor a inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritis. Clin. Exp. Rheumatol. 26, 449-452 (2008). (Pubitemid 352003214)
    • (2008) Clinical and Experimental Rheumatology , vol.26 , Issue.3 , pp. 449-452
    • Yazici, Y.1    Yazici, H.2
  • 8
    • 45749083372 scopus 로고    scopus 로고
    • Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: A survey of power considerations
    • DOI 10.1093/rheumatology/ken190
    • Yazici, Y., Adler, N. M. & Yazici, H. Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations. Rheumatology (Oxford) 47, 1054-1057 (2008). (Pubitemid 351865932)
    • (2008) Rheumatology , vol.47 , Issue.7 , pp. 1054-1057
    • Yazici, Y.1    Adler, N.M.2    Yazici, H.3
  • 9
    • 84970861892 scopus 로고
    • Events per person year can obscure the true risk of certain adverse drug reactions
    • Paterson, K. R. Events per person year. Can obscure the true risk of certain adverse drug reactions. BMJ 310, 1470 (1995).
    • (1995) BMJ , vol.310 , pp. 1470
    • Paterson, K.R.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.